EMEdward J. Mills

Edward J. Mills

*This is an algorithmically generated author record based on publicly available information.

Edward J. Mills has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • REPORTING OF INFORMED CONSENT, STANDARD OF CARE AND POST‐TRIAL OBLIGATIONS IN GLOBAL RANDOMIZED INTERVENTION TRIALS: A SYSTEMATIC SURVEY OF REGISTERED TRIALS

    by Emma R.M. Cohen, Jennifer M. O'Neill, Michel Joffres, Ross E.G. Upshur, Edward Mills

    Ethical guidelines are designed to ensure benefits, protection and respect of participants in clinical research. Clinical trials must now be registered on open-access databases and provide details on ethical considerations. This systematic survey aimed to determine the extent to which recently registered clinical trials report the use of standard of care and post-trial obligations in trial registries, and whether trial characteristics vary according to setting. We selected global randomized trials registered on http://www.clinicaltrials.gov and http://www.controlled-trials.com. We searched for intervention trials of HIV/AIDS, malaria, and tuberculosis from 9 October 2004, the date of the most recent version of the Helsinki Declaration, to 10 April 2007. We collected data from 312 trials. Fifty-eight percent (58%, 95% CI = 53 to 64) of trial protocols report informed consent. Fifty-eight percent (58%, 95% CI = 53 to 64) of trials report active controls. Almost no trials (1%, 95% CI = 0.5 to 3) mention post-trial provisions. Most trials measure surrogate outcomes. Twenty percent (20%, 95% CI = 16 to 25) of trials measure patient-important outcomes, such as death; and the odds that these outcomes are in a low income country are five times greater than for a developed country (odds ratio (OR) 5.03, 95% CI = 2.70 to 9.35, p = < 0.001). Pharmaceutical companies are involved in 28% (CI = 23 to 33) of trials and measure surrogate outcomes more often than nonpharmaceutical companies (OR 2.45, 95% CI = 1.18 to 5.09, p = 0.31). We found a large discrepancy in the quality of reporting and approaches used in trials in developing settings compared to wealthier settings.


  • Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime?

    by Edward J Mills, William A Schabas, Jimmy Volmink, Roderick Walker, Nathan Ford, Elly Katabira, Aranka Anema, Michel Joffres, Pedro Cahn, Julio Montaner


  • Open Access

    In the Era of Systematic Reviews, Does the Size of an Individual Trial Still Matter?

    by Gordon H Guyatt, Edward J Mills, Diana Elbourne

    Systematic reviews that combine high-quality evidence from several trials are now widely considered to be at the top of the hierarchy of clinical evidence. Given the primacy of systematic reviews—and the fact that individual clinical trials rarely provide definitive answers to a clinical research question—some commentators question whether the sample size calculation for an individual trial still matters. Others point out that small trials can still be potentially misleading.


  • Open Access

    Simple, effective interventions are key to improving adherence in marginalized populations.

    by Edward J. Mills, Curtis Cooper

    To assist any marginalized population in poor health, we require simple, effective interventions that are pragmatically accessible. In this issue of Clinical Infectious Diseases, Petersen et al. [1] demonstrate an important association between pillbox use and both improved adherence and decreased HIV load. Considering the low cost and simplicity of this intervention, it represents an important tool to assist patients with HIV infection who are on the threshold of adequate adherence to maximize the potential outcomes possible with their daily combination antiretroviral regimens.


  • Open Access

    Conflict and health: a paradigm shift in global health and human rights

    by Sonal Singh, James J Orbinski, Edward J Mills


  • Open Access

    Health, human rights, and the conduct of clinical research within oppressed populations

    by Edward J Mills, Sonal Singh

    Clinical trials evaluating interventions for infectious diseases require enrolling participants that are vulnerable to infection. As clinical trials are conducted in increasingly vulnerable populations, issues of protection of these populations become challenging. In settings where populations are forseeably oppressed, the conduct of research requires considerations that go beyond common ethical concerns and into issues of international human rights law.


  • The impact of conflict on HIV/AIDS in sub-Saharan Africa

    by Edward J Mills, Sonal Singh, Brett D Nelson, Jean B Nachega

    Sub-Saharan Africa disproportionately represents the largest incidence of both HIV/AIDS and internal conflicts. The impact of conflict on HIV incidence is largely unknown. Current epidemiological evidence paradoxically suggests that in most populations affected by conflict, HIV prevalence is lower than surrounding communities. However, in situations of conflict, the most vulnerable populations, such as women and children, are at increased risk for HIV through sexual violence, forced occupational exposure and an absence of access to health care or testing. Together, these dimensions of conflict create a complex and challenging situation for prevention of HIV/AIDS and delivery of care to conflict-affected populations. We examine the complexity of monitoring HIV/AIDS in conflict settings. We argue that increased efforts are needed to protect vulnerable populations and design health-delivery systems that are sustainable in settings of conflict.


  • Top Cited Papers

    Adherence to Antiretroviral Therapy in Sub-Saharan Africa and North America

    by Edward J. Mills, Jean B. Nachega, Iain Buchan, James Orbinski, Amir Attaran, Sonal Singh, Beth Rachlis, Ping Wu, Curtis Cooper, Lehana Thabane, et al.

    ContextAdherence to antiretroviral therapy is a powerful predictor of survival for individuals living with human immunodeficiency virus (HIV) and AIDS. Concerns about incomplete adherence among patients living in poverty have been an important consideration in expanding the access to antiretroviral therapy in sub-Saharan Africa.ObjectiveTo evaluate estimates of antiretroviral therapy adherence in sub-Saharan Africa and North America.Data SourcesEleven electronic databases were searched along with major conference abstract databases (inclusion dates: inception of database up until April 18, 2006) for all English-language articles and abstracts; and researchers and treatment advocacy groups were contacted.Study Selection and Data AbstractionTo best reflect the general population, studies of mixed populations in both North America and Africa were selected. Studies evaluating specific populations such as men only, homeless individuals, or drug users, were excluded. The data were abstracted in duplicate on study adherence outcomes, thresholds used to determine adherence, and characteristics of the populations. A random-effects meta-analysis was performed in which heterogeneity was examined using multivariable random-effects logistic regression. A sensitivity analysis was performed using Bayesian methods.Data SynthesisThirty-one studies from North America (28 full-text articles and 3 abstracts) and 27 studies (9 full-text articles and 18 abstracts) from sub-Saharan Africa were included. African studies represented 12 sub-Saharan countries. Of the North American studies, 71% used patient self-report to assess adherence; this was true of 66% of the African assessments. Studies reported similar thresholds for adherence monitoring (eg, 100%, >95%, >90%, >80%). A pooled analysis of the North American studies (17 573 patients total) indicated a pooled estimate of 55% (95% confidence interval, 49%-62%; I2, 98.6%) of the populations achieving adequate levels of adherence. Our pooled analysis of African studies (12 116 patients total) indicated a pooled estimate of 77% (95% confidence interval, 68%-85%; I2, 98.4%). Study continent, adherence thresholds, and study quality were significant predictors of heterogeneity. Bayesian analysis was used as an alternative statistical method for combining adherence rates and provided similar findings.ConclusionOur findings indicate that favorable levels of adherence, much of which was assessed via patient self-report, can be achieved in sub-Saharan African settings and that adherence remains a concern in North America.


  • Randomized Trials Stopped Early for Harm in HIV/AIDS: A Systematic Survey

    by Edward Mills, Curtis Cooper, Ping Wu, Beth Rachlis, Sonal Singh, Gordon Guyatt

    Purpose: The decision to stop trials early because of the harmful effects of the intervention is complex and requires weighing statistical, logistical, and ethical considerations. We assessed the prevalence of randomized clinical trials (RCTs) stopped early for harm in HIV/AIDS and determined the quality of reporting of methods to inform the decision to stop the trial. Method: We searched 11 electronic databases and major conference abstract databases, contacted trialist and advocacy groups, and searched the Internet. We selected RCTs stopped early for harm. We extracted data on journal and year of publication, reporting of methods and funding, planned sample size, number and planning of interim analyses, stopping rules, and effect size of the harm outcomes. Results: We found 10 RCTs stopped early for harm (median, n = 85; range, 7-1227). Most interventions (n = 9) were antiviral drugs; one trial studied vitamins to prevent vertical transmission of HIV. Five studies reported a priori defined adverse events, and only 1 trial reported planned stopping guidelines. The primary harm outcomes reported across trials included toxicity, death, and increased mother-to-child transmission. Two trials were stopped due to sudden unanticipated adverse events (Stevens-Johnson syndrome, death, and encephalopathy). Relative risk point estimates for harm ranged from 1 to 6.18. Six studies reported the presence of a data safety and monitoring board. Conclusion: The reporting of methods to inform the decision to stop trials for harm in this population is deficient in a variety of ways, including lack of stopping guidelines. Clinicians should interpret RCTs stopped early for harm with caution and interpret the results in light of related evidence. Trialists should improve the transparency of their decision-making regarding early stopping for harmful effects.